Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 198198, 6 pages
http://dx.doi.org/10.1155/2014/198198
Research Article

Comparison of Two Assays to Determine Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis in relation to Other Chronic Inflammatory Rheumatic Diseases: Assaying Anti-Modified Citrullinated Vimentin Antibodies Adds Value to Second-Generation Anti-Citrullinated Cyclic Peptides Testing

1Programas de Doctorado en Farmacología y en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara, JAL, Mexico
2Hospital General Regional 180 IMSS Tlajomulco, JAL, Mexico
3Unidad de Investigación en Epidemiología Clínica y División de Investigación en Salud, UMAE, Hospital de Especialidades (HE), Centro Médico Nacional de Occidente (CMNO), IMSS, Guadalajara, JAL, Mexico
4Programa de Doctorado en Salud Púbica CUCS, Guadalajara, JAL, Mexico
5Departamento de Fisiologia, CUCS, Universidad de Guadalajara, Guadalajara, JAL, Mexico
6Programa de Servicio Social en Investigación, Secretaria de Salud, Guadalajara, JAL, Mexico
7Decanato Ciencias de la Salud, Universidad Autónoma de Guadalajara, Mexico
8Dirección de la División de Disciplinas para el Desarrollo, Promoción y Preservación de la Salud, CUCS, Universidad de Guadalajara, Mexico
9Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, JAL, Mexico
10Avenida Salto del Agua 2192, Colonia Jardines del Country, Guadalajara, Mexico

Received 5 March 2014; Revised 30 April 2014; Accepted 23 May 2014; Published 15 June 2014

Academic Editor: Juan-Manuel Anaya

Copyright © 2014 Miriam Lizette Díaz-Toscano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Rindfleisch and D. Muller, “Diagnosis and management of rheumatoid arthritis,” The American Family Physician, vol. 72, no. 6, pp. 1037–1047, 2005. View at Google Scholar · View at Scopus
  2. J. I. Gamez-Nava, L. Gonzalez-Lopez, P. Davis, and M. E. Suarez-Almazor, “Referral and diagnosis of common rheumatic diseases by primary care physicians,” British Journal of Rheumatology, vol. 37, no. 11, pp. 1215–1219, 1998. View at Google Scholar · View at Scopus
  3. M. A. M. van Boekel, E. R. Vossenaar, F. H. J. van den Hoogen, and W. J. van Venrooij, “Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value,” Arthritis Research, vol. 4, no. 2, pp. 87–93, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Aletaha, T. Neogi, and A. J. Silman, “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 69, pp. 1580–1588, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Taylor, J. Gartemann, J. Hsieh, and J. Creeden, “A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis,” Autoimmune Diseases, vol. 1, no. 1, Article ID 815038, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Zintzaras, A. A. Papathanasiou, D. C. Ziogas, and M. Voulgarelis, “The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates,” BMC Musculoskeletal Disorders, vol. 13, article 113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Poulsom and P. J. Charles, “Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis,” Clinical Reviews in Allergy and Immunology, vol. 34, no. 1, pp. 4–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Wagner, M. Skoumal, P. M. Bayer, and K. Klaushofer, “Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis,” Rheumatology International, vol. 29, no. 11, pp. 1315–1321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Dejaco, W. Klotz, H. Larcher, C. Duftner, M. Schirmer, and M. Herold, “Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 8, no. 4, article R119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Raza, L. Mathsson, C. D. Buckley, A. Filer, and J. Rönnelid, “Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis,” Annals of the Rheumatic Diseases, vol. 69, no. 3, pp. 627–628, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Ursum, M. M. J. Nielen, D. van Schaardenburg et al., “Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study,” Arthritis Research and Therapy, vol. 10, no. 1, article R12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Liu, R. Jia, J. Zhao, and Z. Li, “The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis,” Journal of Rheumatology, vol. 36, no. 6, pp. 1136–1142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Bang, K. Egerer, A. Gauliard et al., “Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis,” Arthritis and Rheumatism, vol. 56, no. 8, pp. 2503–2511, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Besada, C. Nikolaisen, and H. Nossent, “Diagnostic value of antibodies against mutated citrullinated vimentin for rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 29, no. 1, pp. 85–88, 2011. View at Google Scholar · View at Scopus
  15. T. Zhu and L. Feng, “Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients,” International Journal of Rheumatic Diseases, vol. 16, no. 2, pp. 157–161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Bartoloni, A. Alunno, O. Bistoni et al., “Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature,” Autoimmunity Reviews, vol. 11, no. 11, pp. 815–820, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Google Scholar · View at Scopus
  18. A. Doria, P. Vesco, F. Zulian, and P. F. Gambari, “The 1982 ARA/ACR criteria for the classification of systemic lupus erythematosus in pediatric and adult patients,” Clinical and Experimental Rheumatology, vol. 12, no. 6, pp. 689–690, 1994. View at Google Scholar · View at Scopus
  19. S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria,” Arthritis and Rheumatism, vol. 27, no. 4, pp. 361–368, 1984. View at Google Scholar · View at Scopus
  20. A. T. Masi, G. P. Rodnan, and T. A. Medsger, “Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee,” Arthritis and Rheumatism, vol. 23, no. 5, pp. 581–590, 1980. View at Google Scholar · View at Scopus
  21. M. L. L. Prevoo, M. A. Van 'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 38, no. 1, pp. 44–48, 1995. View at Publisher · View at Google Scholar · View at Scopus
  22. M. H. Cardiel, M. Abello-Banfi, R. Ruiz-Mercado, and D. Alarcón-Segovia, “How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI),” Clinical and Experimental Rheumatology, vol. 11, no. 2, pp. 117–121, 1993. View at Google Scholar · View at Scopus
  23. A. M. El-Barbary, E. M. Kassem, M. A. S. El-Sergany, S. A.-M. Essa, and M. A. Eltomey, “Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide,” Journal of Rheumatology, vol. 38, no. 5, pp. 828–834, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Al-Shukaili, S. Al-Ghafri, S. Al-Marhoobi, and J. Alkaabi, “Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies and rheumatoid factor in omani patients with rheumatoid arthritis,” International Journal of Rheumatology, vol. 2012, Article ID 285854, 5 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. H. C. Maraina, A. K. Nurdayana, D. Rusni, and Y. Azwany, “Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis,” International Journal of Rheumatic Diseases, vol. 13, no. 4, pp. 335–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Rantapää-Dahlqvist, B. A. W. De Jong, E. Berglin et al., “Antibodies against cyclic citrullinated peptide and iga rheumatoid factor predict the development of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 48, no. 10, pp. 2741–2749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Mathsson, M. Mullazehi, M. C. Wick et al., “Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides,” Arthritis and Rheumatism, vol. 58, no. 1, pp. 36–45, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. E. L. Gomez, S. C. Gun, S. D. Somanath, K. Chinna, and A. K. Radhakrishnan, “Ethnic differences in the prognostic utility of rheumatoid factor isotypes and anticyclic citrullinated peptides in rheumatoid arthritis patients: a cross-sectional study,” Modern Rheumatology, vol. 23, no. 4, pp. 716–721, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Nicaise-Roland, L. Nogueira, C. Demattei et al., “Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort,” Annals of the Rheumatic Diseases, vol. 72, no. 3, pp. 357–362, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. E. R. Vossenaar, N. Després, E. Lapointe et al., “Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin,” Arthritis Research & Therapy, vol. 6, no. 2, pp. R142–150, 2004. View at Google Scholar · View at Scopus
  31. G. A. Schellekens, B. A. W. de Jong, F. H. J. van den Hoogen, L. B. A. van de Putte, and W. J. van Venrooij, “Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies,” Journal of Clinical Investigation, vol. 101, no. 1, pp. 273–281, 1998. View at Google Scholar · View at Scopus
  32. K. N. Verpoort, K. Cheung, A. Ioan-Facsinay et al., “Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles,” Arthritis and Rheumatism, vol. 56, no. 12, pp. 3949–3952, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. O. Vittecoq, B. Inçaurgarat, F. Jouen-Beades et al., “Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis,” Clinical and Experimental Immunology, vol. 135, no. 1, pp. 173–180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Saraux, J. M. Berthelot, V. Devauchelle et al., “Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis,” Journal of Rheumatology, vol. 30, no. 12, pp. 2535–2539, 2003. View at Google Scholar · View at Scopus
  35. Z. Szekanecz, Z. Szabó, M. Zeher et al., “Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population,” Immunologic Research, vol. 56, no. 2-3, pp. 439–443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Shidara, E. Inoue, E. Tanaka et al., “Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis,” Rheumatology International, vol. 31, no. 5, pp. 617–622, 2011. View at Publisher · View at Google Scholar · View at Scopus